A 6-Month Extension Study of OTO-104 in Meniere's Disease
Status:
Terminated
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label extension study of a single intratympanic injection of OTO-104 given
every 3 months for a total of 2 injections. Subjects must have completed either Otonomy study
104-201102 (Phase 2b study of OTO-104) or 104-201506 (Phase 3 study of OTO-104) in order to
be eligible for this open-label extension study.